The Present study Lornoxicam (LOX) is a mainstay Non Steroidal Anti Inflammatory Drug
(NSAID) for the treatment of inflammatory diseases like Rheumatoid Arthritis (RA) and
Osteoarthritis (OA). But this drug has shorter half life (3-4 hours) and induces side effects
when used for long term. The aim of the present study is
To formulate controlled porosity osmotic tablets of LOX using mannitol as osmogen.
To increase the solubility of LOX using tromethamine as solubility modifier and SLS as
wicking agent.
To release LOX in a controlled manner osmotically with cellulose acetate coating along
with sorbitol as a pore former.
The main objective of the study is to produce controlled release of LOX for the
pain management of RA and OA and to improve the efficacy and patient compliance
